Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and negatively regulates tumor growth

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Rhabdomyosarcoma is a prevalent childhood soft tissue sarcoma.
• Alveolar rhabdomyosarcoma (ARMS) exhibits poor prognosis with <30% 5-year survival.
• Caveolin-1 (CAV1) is implicated as a potential tumor suppressor in various cancers.

Purpose of the Study:

• To investigate the role of Caveolin-1 (CAV1) in alveolar rhabdomyosarcoma (ARMS).
• To determine if CAV1 functions as a tumor suppressor in ARMS.
• To explore the mechanisms underlying CAV1 regulation and its functional impact.

Main Methods:

• Comparative analysis of CAV1 expression in ARMS versus other rhabdomyosarcoma (RMS) subtypes.
• DNA methylation analysis of the CAV1 promoter region.
• Azacytidine treatment to assess epigenetic silencing and re-expression.
• Functional studies involving CAV1 reintroduction in ARMS cell lines (in vitro).
• Xenograft models to evaluate CAV1 effects in vivo.

Main Results:

• CAV1 expression is significantly reduced or absent in ARMS cell lines and tumors.
• Epigenetic mechanisms, specifically promoter DNA methylation, contribute to CAV1 silencing.
• Re-expression of CAV1 inhibits ARMS cell proliferation and clonogenic potential.
• CAV1 reintroduction promotes muscular differentiation markers (e.g., CAV3) and MAPK pathway inhibition.
• In vivo studies show CAV1-expressing xenografts exhibit delayed growth, differentiation, and increased cell death.

Conclusions:

• CAV1 acts as a potent tumor suppressor in alveolar rhabdomyosarcoma.
• Loss of CAV1 function contributes to uncontrolled proliferation in ARMS.
• Targeting CAV1 may offer a therapeutic strategy for ARMS treatment.